Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug133 | ARGX-117 Wiki | 1.00 |
drug4657 | placebo+rHuPH20 Wiki | 1.00 |
drug2248 | MRI scans Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
This is a phase 1, first-in-human, double-blinded, randomized, placebo-controlled, escalating single and multiple dose levels trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ARGX-117 administered IV and/or SC. Up to 104 healthy, adult male and female subjects of non-childbearing potential will be enrolled in this trial.
Description: Maximum observed serum concentration
Measure: Maximum serum concentrations (Cmax) Time: Up to 17 weeks (arm 1) and up to 22 weeks (arm 2)Description: Time calculated to reach Cmax
Measure: Time to reach maximum serum concentrations (Tmax) Time: Up to 17 weeks (arm 1) and up to 22 weeks (arm 2)Description: Functional complement activity
Measure: Free C2 concentration Time: Up to 17 weeks (arm 1) and up to 22 weeks (arm 2)Description: Functional complement activity
Measure: Total C2 concentration Time: Up to 17 weeks (arm 1) and up to 22 weeks (arm 2)Description: Functional complement activity
Measure: CH50 titers Time: Up to 17 weeks (arm 1) and up to 22 weeks (arm 2)Description: Immunogenicity against ARGX-117
Measure: Level of anti-drug antibodies Time: Up to 17 weeks (arm 1) and up to 22 weeks (arm 2)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports